Sexually transmitted diseases and the increased risk for HIV transmission: Implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions

Journal of Acquired Immune Deficiency Syndromes

Volumn 24, Issue 1, 2000, Pages 48-56

  Chesson, Harrell W ^a,c   Pinkerton, Steven D ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Bernoulli model; HIV AIDS; Prevention; Sexually transmitted diseases

Indexed keywords

ARTICLE; CHLAMYDIASIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SIMULATION; EVALUATION; GENITAL HERPES; GONORRHEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; MATHEMATICAL MODEL; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PROBABILITY; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; VIRUS TRANSMISSION;

EID: 0034190638     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200005010-00009     Document Type: Article

References (102)

1. Institute of Medicine. The hidden epidemic: confronting sexually transmitted diseases. Washington, DC: National Academy Press: 1997.
2. Howell MR, Quinn TC, Brathwaite W, Gaydos CA. Screening women for chlamydia trachomatis in family planning clinics: the cost-effectiveness of DNA amplification assays. Sex Transm Dis 1998;25:108-17.
3. Peterman TA, Toomey KE, Dicker LW, Zaidi AA, Wroten JE, Carolina J. Partner notification for syphilis: a randomized, controlled trial of three approaches. Sex Transm Dis 1997;24:511-8.
4. Howell MR, Kassler WJ, Haddix A. Partner notification to prevent pelvic inflammatory disease in women. Cost-effectiveness of two strategies. Sex Transm Dis 1997;24:287-92.
5. Haddix AC, Hillis SD, Kassler WJ. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis 1995;22:274-80.
6. Abyad A. Cost-effectiveness of antenatal screening for syphilis. Health Care Women Int 1995;16:323-8.
7. Ernst AA, Samuels JD, Winsemius DK. Emergency department screening for syphilis in patients with other suspected sexually transmitted diseases. Ann Emerg Med 1991;20:627-30.
8. Phillips RS, Safran C, Aronson MD, Taylor WC. Should women be tested for gonococcal infection of the cervix during routine gynecologic visits? An economic appraisal. Am J Med 1989;86: 297-302.
9. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999;75:3-17.
10. Cohen MS. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 1998;351(Suppl 3):5-7.
11. Centers for Disease Control and Prevention. HIV prevention through early detection and treatment of other sexually transmitted diseases- United States. MMWR Morb Mortal Wkly Rep 1998;47(RR-12):1-24.
12. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992;19:61-77.
13. Fiscus SA, Vernazza PL, Gilliam B, Dyer J, Eron JJ, Cohen MS. Factors associated with changes in HIV shedding in semen. AIDS Res Hum Retroviruses 1998;14(SuppI 1):S27-31.
14. Dezzutti CS, Lal RB. Mechanisms of HIV transmission through epithelial cell barriers [abstract 32124]. Presented at the XII World AIDS Conference, Geneva, Switzerland, 1998.
15. Plummer FA. Heterosexual transmission of human immunodeficiency virus type 1 (HIV): interactions of conventional sexually transmitted diseases, hormonal contraception and HIV-1. AIDS Res Hum Retroviruses 1998;14(Suppl 1):S5-10.
16. Nelson KE, Rungruengthanakit K, Margolick J, et al. High rates of transmission of subtype E human immunodeficiency virus type 1 among heterosexual couples in Northern Thailand: role of sexually transmitted diseases and immune compromise. J Infect Dis 1999;180:337-43.
17. Dyer JR, Eron JJ, Hoffman IF, et al. Association of CD4 cell depletion and elevated blood and seminal plasma human immunodeficiency virus type 1 (HIV-1) RNA concentrations with genital ulcer disease in HIV-1-infected men in Malawi. J Infect Dis 1998;177:224-7.
18. John GC, Nduati RW, Mbori-Ngacha D, et al. Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis 1997; 175:57-62.
19. Mostad SB, Overbaugh J, DeVange DM, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997;350:922-7.
20. Anderson DJ, O'Brien TR, Politch JA, et al. Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. JAMA 1992;267:2769-74.
21. Moss GB, Overbaugh J, Welch M, et al. Human immunodeficiency virus DNA in urethral secretions in men: association with gonococcal urethritis and CD4 cell depletion. J Infect Dis 1995; 172:1469-74.
22. Mbizvo MT, Machekano R, McFarland W, et al. HIV seroincidence and correlates of seroconversion in a cohort of male factory workers in Harare, Zimbabwe. AIDS 1996;10:895-901.
23. Nopkesom T, Mock PA, Mastro TD, et al. HIV-1 subtype E incidence and sexually transmitted diseases in a cohort of military conscripts in northern Thailand. J Acquir Immune Defic Syndr 1998;18:372-9.
24. Nelson KE, Eiumtrakul S, Celentano D, et al. The association of herpes simplex virus type 2 (HSV-2), Haemophilus ducreyi, and syphilis with HIV infection in young men in northern Thailand. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:293-300.
25. Kuiken CL, van Griensven GJ, de Vroome EM, Coutinho RA. Risk factors and changes in sexual behavior in male homosexuals who seroconverted for human immunodeficiency virus antibodies. Am J Epidemiol 1990;132:523-30.
26. Kapiga SH, Lyamuya EF, Lwihula GK, Hunter DJ. The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS 1998;12:75-84.
27. Plourde PJ, Pepin J, Agoki E, et al. Human immunodeficiency virus type 1 seroconversion in women with genital ulcers. J Infect Dis 1994;170:313-7.
28. Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 1998;12:1699-706.
29. Weir SS, Feldblum PJ, Roddy RE, Zekeng L. Gonorrhea as a risk factor for HIV acquisition. AIDS 1994;8:1605-8.
30. Osewe PL, Peterman TA, Ransom RL, Zaidi AA, Wroten JE. Trends in the acquisition of sexually transmitted diseases among HIV-positive patients at STD clinics, Miami 1988-1992. Sex Transm Dis 1996;23:230-3.
31. Dominguez K, Ellerbrock TV, Harrington PE, Bush T, Malecki J, Simonds RJ. Risk factors for HIV seroconversion among young women in a rural community in the southeastern United States [abstract C.222]. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, 1996.
32. Kilmarx PH, Limpakarnjanarat K, Mastro TD, et al. HIV-1 seroconversion in a prospective study of female sex workers in northern Thailand: continued high incidence among brothel-based women. AIDS 1998;12:1889-98.
33. Kilmarx PH, Yanparsan S, Bunnell RE, et al. Declining sero-prevalence of HIV-1 among child-bearing women in upper northern Thailand [abstract 13143]. Presented at the XII World AIDS Conference, Geneva, Switzerland, 1998.
34. Eron JJ, Jr, Gilliam B, Fiscus S, Dyer J, Cohen MS. HIV-1 shedding and chlamydial urethritis. JAMA 1996;275:36.
35. Telzak EE, Chiasson MA, Bevier PJ, Stoneburner RL, Castro KG, Jaffe HW. HIV-1 seroconversion in patients with and without genital ulcer disease. A prospective study. Ann Intern Med 1993;119:1181-6.
36. Craib KJ, Meddings DR, Strathdee SA, et al. Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men. Genitourin Med 1995;71:150-4.
37. Quinn TC. Association of sexually transmitted diseases and infection with the human immunodeficiency virus: biological cofactors and markers of behavioural interventions. Int J STD AIDS 1996;7(Suppl 2):17-24.
38. Clemetson DB, Moss GB, Willerford DM, et al. Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA 1993;269:2860-4.
39. Keet IP, Lee FK, van Griensven GJ, Lange JM, Nahmias A, Coutinho RA. Herpes simplex virus type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisition. Genitourin Med 1990;66:330-3.
40. Quinn TC, Cannon RO, Glasser D, et al. The association of syphilis with risk of human immunodeficiency virus infection in patients attending sexually transmitted disease clinics. Arch Intern Med 1990;150:1297-302.
41. Royce RA, Sena A, Cates W, Jr., Cohen MS. Sexual transmission of HIV [published erratum appears in N Engl J Med 1997;337: 799]. N Engl J Med 1997;336:1072-8.
42. Plummer FA, Simonsen JN, Cameron DW, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis 1991;163:233-9.
43. de Vincenzi I, Ancelle-Park R. Heterosexual transmission of HIV: a European study. I: male-to- female transmission [abstract T.A.P.98]. Presented at the V World Conference on AIDS, Montreal, Quebec, Canada 1989.
44. Kassler WJ, Zenilman JM, Erickson B, Fox R, Peterman TA, Hook EW III. Seroconversion in patients attending sexually transmitted disease clinics. AIDS 1994;8:351-5.
45. Otten MW, Jr., Zaidi AA, Peterman TA, Rolfs RT, Witte JJ. High rate of HIV seroconversion among patients attending urban sexually transmitted disease clinics. AIDS 1994;8:549-53.
46. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993;7:95-102.
47. Laga M, Alary M, Nzila N, et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 1994;344:246-8.
48. Holmberg SD, Stewart JA, Gerber AR, et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA 1988;259:1048-50.
49. Sewankambo N, Gray RH, Wawer MJ, et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997;350:546-50.
50. Mehendale SM, Rodrigues JJ, Brookmeyer RS, et al. Incidence and predictors of human immunodeficiency virus type 1 seroconversion in patients attending sexually transmitted disease clinics in India. J Infect Dis 1995;172:1486-91.
51. Ghys PD, Fransen K, Diallo MO, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS 1997;11:F85-93.
52. Kreiss JK, Coombs R, Plummer F, et al. Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J Infect Dis 1989;160:380-4.
53. Plummer FA, Wainberg MA, Plourde P, et al. Detection of human immunodeficiency virus type 1 (HIV-1) in genital ulcer exudate of HIV-1-infected men by culture and gene amplification. J Infect Dis 1990;161:810-1.
54. Schacker T, Ryncarz AJ, Goddard J, et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998;280:61-6.
55. Atkins MC, Carlin EM, Emery VC, Griffiths PD, Boag F. Fluctuations of HIV load in semen of HIV positive patients with newly acquired sexually transmitted diseases. BMJ 1996;313: 341-2.
56. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599-605.
57. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1997;349:1868-73.
58. Spinola SM, Orazi A, Arno JN, et al. Haemophilus ducreyi elicits a cutaneous infiltrate of CD4 cells during experimental human infection. J Infect Dis 1996;173:394-402.
59. Levine WC, Pope V, Bhoomkar A, et al. Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Infect Dis 1998;177:167-74.
60. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995;346:530-6.
61. Over M, Piot P. Human immunodeficiency virus infection and other sexually transmitted diseases in developing countries: public health importance and priorities for resource allocation. J Infect Dis 1996;174(Suppl 2):S162-75.
62. Boily MC, Brunham RC. The impact of HIV and other STDs on human populations: are predictions possible? Infect Dis Clin North Am 1993;7:771-92 [published erratum appears in Infect Dis Clin North Am 1994;8:xi-xii].
63. Robinson NJ, Mulder DW, Auvert B, Hayes RJ. Proportion of HIV infections attributable to other sexually transmitted diseases in a rural Ugandan population: simulation model estimates. Int J Epidemiol 1997;26:180-9.
64. Auvert B, Moore M, Bertrand WE, et al. Dynamics of HIV infection and AIDS in central African cities. Int J Epidemiol 1990; 19:417-28.
65. Renton AM, Whitaker L, Riddlesdell M. Heterosexual HIV transmission and STD prevalence: predictions of a theoretical model. Sex Transm Infect 1998;74:339-44.
66. Chesson HW, Pinkerton SD, Irwin KL, Rein D, Kassler WJ. New HIV cases attributable to syphilis in the USA: estimates from a simplified transmission model. AIDS 1999;13:1387-96.
67. Weinstein MC, Graham JD, Siegel JE, Fineberg HV. Cost-effectiveness analysis of AIDS prevention programs: concepts, complications, and illustrations. In: Turner CF, Miller HG, Moses LE, eds. Confronting AIDS: sexual behavior and intravenous drug use. Washington, DC: National Academy Press, 1989:471-99.
68. Pinkerton SD, Abramson PR. The Bernoulli-process model of HIV transmission: applications and implications. In Holtgrave DR, ed. Handbook of economic evaluation of HIV prevention programs. New York: Plenum Press, 1998:13-33.
69. Pinkerton SD, Abramson PR. Evaluating the risks: a Bernoulli process model of HIV infection and risk reduction. Eval Rev 1993;18:504-28.
70. Holtgrave DR, Leviton LC, Wagstaff DA, Pinkerton SD. Cumulative probability of HIV infection: a summary risk measure for HIV prevention intervention studies. AIDS Behav 1997;1:169-72.
71. Moses S, Plummer FA, Ngugi EN, Nagelkerke NJ, Anzala AO, Ndinya-Achola JO. Controlling HIV in Africa: effectiveness and cost of an intervention in a high-frequency STD transmitter core group. AIDS 1991;5:407-11.
72. Fineberg HV. Education to prevent AIDS: prospects and obstacles. Science 1988;239:592-6.
73. American Social Health Association. Sexually transmitted diseases in America: how many cases and at what cost? Menlo Park, CA: Kaiser Family Foundation, 1998.
74. Division of STD Prevention. Sexually transmitted disease surveillance, 1996. Atlanta: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, 1997.
75. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:54-62.
76. Kramer MA, Aral SO, Curran JW. Self-reported behavior patterns of patients attending a sexually transmitted disease, clinic. Am J Public Health 1980;70:997-1000.
77. European Study Group. Risk factors for male to female transmission of HIV. BMJ 1989;298:411-5.
78. Lazzarin A, Saracco A, Musicco M, Nicolosi A. Man-to-woman sexual transmission of the human immunodeficiency virus. Risk factors related to sexual behavior, man's infectiousness, and woman's susceptibility [published erratum appears in Arch Intern Med 1992;152:876]. Arch Intern Med 1991;151:2411-6.
79. Holtgrave DR, Kelly JA. Preventing HIV/AIDS among high-risk urban women: the cost- effectiveness of a behavioral group intervention. Am J Public Health 1996;86:1442-5.
80. Boyer CB, Barrett DC, Peterman TA, Bolan G. Sexually transmitted disease (STD) and HIV risk in heterosexual adults attending a public STD clinic: evaluation of a randomized controlled behavioral risk-reduction intervention trial. AIDS 1997;11:359-67.
81. Hook EW III, Richey CM, Leone P, et al. Delayed presentation to clinics for sexually transmitted diseases by symptomatic patients. A potential contributor to continuing STD morbidity. Sex Transm Dis 1997;24:443-8.
82. Fortenberry JD. Health care seeking behaviors related to sexually transmitted diseases among adolescents. Am J Public Health 1997;87:417-20.
83. Aral SO, Wasserheit J. STD-related health care seeking and health service delivery. In: Holmes KK, Sparling PF, Mårdh P, et al., eds. Sexually transmitted diseases. New York: McGraw-Hill, 1999:1295-1305.
84. Cates W, Jr., Rothenberg RB, Blount JH. Syphilis control. The historic context and epidemiologic basis for interrupting sexual transmission of Treponema pallidum. Sex Transm Dis 1996;23: 68-75.
85. Anderson RM. Transmission dynamics of sexually transmitted infections. In Holmes KK, Sparling PF, Mårdh P, et al., eds. Sexually transmitted diseases. New York: McGraw-Hill, 1999: 25-37.
86. Corey L, Wald A. Genital herpes. In Holmes KK, Sparling PF, Mårdh P, et al., eds. Sexually transmitted diseases. New York: McGraw-Hill, 1999:285-312.
87. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985;12:33-9.
88. Mastro TD, de Vincenzi I. Probabilities of sexual HIV-1 transmission. AIDS 1996;10(Suppl A):S75-82.
89. Hayes RJ, Schulz KF, Plummer FA. The cofactor effect of genital ulcers on the per-exposure risk of HIV transmission in sub-Saharan Africa. J Trop Med Hyg 1995;98:1-8.
90. Rehle TM, Saidel TJ, Hassig SE, Bouey PD, Gaillard EM, Sokal DC. AVERT: a user-friendly model to estimate the impact of HIV/sexually transmitted disease prevention interventions on HIV transmission. AIDS 1998;12(Suppl 2):S27-35.
91. Blocker, ME, Levine WC, St Louis ME. HIV co-infection in patients with syphilis, United States [abstract D7]. Presented at the National STD Prevention Conference, Dallas, Texas, 1998.
92. Centers for Disease Control and Prevention. Outbreak of primary and secondary syphilis- Baltimore City, Maryland 1995. MMWR Morbid Mortal Wkly Rep 1996;45:166-9.
93. Cannon RO, Schmid GP, Moore PS, Pappaioanou M. Human immunodeficiency virus (HIV) seroprevalence in persons attending STD clinics in the United States, 1985-1987. Sex Transm Dis 1989;16:184-9.
94. Rosenberg PS. Scope of the AIDS epidemic in the United States. Science 1995;270:1372-5.
95. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996;86: 642-54.
96. Torian LV, Weisfuse IB, Makki HA, et al. Increasing HIV-1 seroprevalence associated with genital ulcer disease, New York City, 1990-1992. AIDS 1995;9:177-81.
97. Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998;178:1795-8.
98. Pinkerton SD, Abramson PR. Not all behavior change is equivalent. Am J Public Health 1998;88:684.
99. Boily MC. Transmission dynamics of coexisting chlamydial and HIV infections in the United States. In: Eng TR, Butler WT, eds. The hidden epidemic: confronting sexually transmitted diseases. Washington, DC: National Academy Press, 1997:316-29.
100. Rothenberg R, Wasserheit J, St Louis M. Estimating the effect of treating sexually transmitted diseases (STDs) on HIV transmission. National HIV/STD Interaction Study Group [abstract 23369]. Presented at the XII World AIDS Conference, Geneva, Switzerland, 1998.
101. Kaplan EH. Modeling HIV infectivity: must sex acts be counted? J Acquir Immune Defic Syndr 1990;3:55-61.
102. Blower SM, Boe C. Sex acts, sex partners, and sex budgets: implications for risk factor analysis and estimation of HIV transmission probabilities. J Acquir Immune Defic Syndr 1993;6: 1347-52.